December 20, 2012 Trading Market Activity

Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that in view of the market activity in the Company’s stock on Thursday, December 20, 2012, the New York Stock Exchange contacted the Company on December 24, 2012, in accordance with the Exchange's usual practice. The Company stated that its policy is not to comment on market activity.

Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business ( www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, RF devices, implanters, introducer products and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics’ brachytherapy business manufactures, markets and distributes “seeds” used primarily in the minimally invasive treatment of localized prostate cancer. The Company’s brachytherapy product line includes its palladium-103 TheraSeed ® device and its iodine-125 AgX100™ device ( www.theragenicsbrachy.com). The terms "Company," "we," "us," or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.

All forward looking statements and cautionary statements included in this document are made as of the date hereof based on information available to us as of the date hereof, and we assume no obligation to update any forward looking statement or cautionary statement.

If you liked this article you might like

Theragenics Corporation Stock Downgraded (TGX)

Theragenics' CEO Discusses Q2 2012 Results - Earnings Call Transcript

7 Stocks Under $10 Soaring Higher

Theragenics Corporation CEO Discusses Q1 2012 Results - Earnings Call Transcript

Theragenics Corporation Stock Upgraded (TGX)